Silvia Novello
#146,283
Most Influential Person Now
Researcher
Silvia Novello's AcademicInfluence.com Rankings
Silvia Novellobiology Degrees
Biology
#10637
World Rank
#13981
Historical Rank
Biotechnology
#156
World Rank
#158
Historical Rank
Download Badge
Biology
Silvia Novello's Degrees
- PhD Biomedical Sciences University of Milan
- Masters Biology University of Turin
Similar Degrees You Can Earn
Why Is Silvia Novello Influential?
(Suggest an Edit or Addition)Silvia Novello's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer (2018) (3740)
- Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer (2018) (2078)
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. (2014) (764)
- Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. (2003) (762)
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019) (627)
- Prevalence of adrenal incidentaloma in a contemporary computerized tomography series (2006) (606)
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. (2016) (575)
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2020) (470)
- Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. (2005) (447)
- Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. (2017) (438)
- Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. (2010) (436)
- Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. (2017) (400)
- Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase (2006) (378)
- ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. (2006) (331)
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. (2008) (323)
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (309)
- Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. (2009) (257)
- The Biology of Epidermal Growth Factor Receptor in Lung Cancer (2004) (252)
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. (2015) (238)
- Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer (2003) (215)
- Lung cancer in never smokers: a different disease (2014) (215)
- Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study (2018) (214)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
- The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review (2008) (197)
- The emerging role of MET/HGF inhibitors in oncology. (2013) (185)
- Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification (2018) (176)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. (2012) (166)
- Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. (1999) (165)
- Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. (2014) (160)
- ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study (2016) (150)
- Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report. (2019) (148)
- Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. (2005) (145)
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study (2015) (140)
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer (2009) (135)
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. (2020) (134)
- Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. (2012) (134)
- OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC (2018) (133)
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. (2020) (130)
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. (2018) (130)
- Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). (2010) (127)
- Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. (2011) (124)
- Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. (2014) (120)
- Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. (2001) (118)
- Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer (2007) (106)
- Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). (2018) (104)
- Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. (2006) (104)
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. (2017) (102)
- The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations. (2013) (99)
- Nonsmall cell lung cancer in never smokers (2009) (97)
- Multidrug resistance in non-small-cell lung cancer. (1999) (91)
- Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. (2015) (91)
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. (2019) (90)
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. (2017) (89)
- The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. (2012) (88)
- The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. (2017) (81)
- Clinicopathologic Features of Advanced Squamous NSCLC. (2016) (80)
- Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield (2007) (80)
- First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. (2020) (78)
- Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 (2019) (75)
- Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung (2009) (72)
- Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. (2010) (72)
- A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics (2019) (70)
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
- Polymerase η mRNA Expression Predicts Survival of Non–Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy (2009) (69)
- Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. (2004) (67)
- Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer (2009) (66)
- Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. (2009) (65)
- Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. (2018) (63)
- Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. (2006) (63)
- A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. (2000) (62)
- 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. (2021) (62)
- 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival (2020) (60)
- High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC (2008) (58)
- Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma (2015) (56)
- Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. (2015) (55)
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. (2015) (55)
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (2010) (53)
- Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin (2009) (52)
- Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer (2014) (51)
- Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. (2003) (51)
- Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases (2014) (50)
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer (2016) (50)
- Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment (2016) (50)
- Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. (2013) (49)
- Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer (2004) (48)
- NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (47)
- ATF2 contributes to cisplatin resistance in non‐small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway (2015) (47)
- Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 (2018) (47)
- Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma (2003) (47)
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients (2013) (46)
- Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma (2018) (46)
- HER‐2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma (2002) (46)
- Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases (2011) (45)
- Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. (2013) (45)
- Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
- Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe (2020) (44)
- MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens. (2015) (43)
- Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (2012) (42)
- Excision Repair Cross Complementing-1 and Topoisomerase II&agr; Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective Study (2008) (41)
- Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. (2019) (41)
- Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study (2016) (40)
- Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. (2016) (40)
- Outcomes of First‐Generation EGFR‐TKIs Against Non‐Small‐Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE‐POSITIVE Study (2018) (40)
- [Breast cancer in the early stage]. (2012) (39)
- Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment (2018) (39)
- Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer (2006) (39)
- Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. (2019) (38)
- Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. (2013) (38)
- Fatigue in lung cancer patients: symptom burden and management of challenges (2016) (38)
- Caveolin‐1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases (2009) (38)
- Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study (2007) (37)
- Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. (2019) (37)
- Extending survival of stage IV non-small cell lung cancer. (2014) (36)
- Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. (2019) (34)
- Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro (2018) (33)
- Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. (2015) (33)
- Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First‐Line Therapy in Patients with Extensive‐Disease Small Cell Lung Cancer (2019) (33)
- Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario. (2017) (32)
- Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. (2017) (32)
- Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research. (2017) (32)
- Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. (2012) (32)
- Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. (2018) (31)
- Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. (2019) (31)
- OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma (2017) (31)
- Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC (2014) (31)
- A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. (2006) (30)
- Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer (2017) (30)
- Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. (2010) (29)
- Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer (2005) (29)
- RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). (2019) (28)
- Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042 (2019) (28)
- Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). (2013) (28)
- Adjuvant therapy in completely resected non-small-cell lung cancer (2003) (28)
- Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study (2017) (28)
- Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients (2014) (27)
- EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. (2019) (27)
- Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. (2014) (27)
- Maintenance therapy in NSCLC: why? To whom? Which agent? (2011) (27)
- Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). (2004) (26)
- Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. (2005) (26)
- KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges. (2020) (25)
- Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (2018) (25)
- Updated clinical information on multitargeted antifolates in lung cancer. (2009) (25)
- Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer (2012) (24)
- Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence‐Based Proposal (2018) (24)
- Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma. (2018) (24)
- OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab (2017) (24)
- Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome (2014) (24)
- Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer? (2016) (24)
- Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. (2019) (24)
- LIGHT/TNFSF14 Promotes Osteolytic Bone Metastases in Non‐small Cell Lung Cancer Patients (2019) (24)
- Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 (2019) (24)
- An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). (2016) (23)
- Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First‐Line Platinum‐Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS‐lung Trial (2017) (23)
- Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (23)
- Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. (2019) (23)
- Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy (2018) (23)
- Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysis. (2013) (23)
- Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. (2010) (22)
- Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer (2007) (22)
- New emerging targets in cancer immunotherapy: the role of VISTA (2020) (22)
- 1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC) (2017) (22)
- Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. (2013) (22)
- Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. (2021) (22)
- Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study (2007) (22)
- Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study. (2021) (21)
- An Open‐Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC‐A12) as a First‐Line Therapy in Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer (2017) (21)
- A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). (2014) (21)
- Role of erythropoietin in the treatment of lung cancer associated anaemia. (2001) (21)
- Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients. (2018) (20)
- International tailored chemotherapy adjuvant trial: ITACA trial. (2011) (19)
- Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. (2020) (19)
- Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. (2007) (19)
- Retrospective Multicenter Study Investigating the Role of Targeted Next‐Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung (2016) (19)
- Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? (2020) (19)
- Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy. (2012) (19)
- Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors (2015) (18)
- Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
- Baseline thymidylate synthase expression according to histological subtypes of non-small cell lung cancer. (2009) (18)
- Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 (2021) (18)
- Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial (2022) (18)
- Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study (2014) (18)
- Abstract CT043: Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results from the KEYNOTE-189 study (2019) (18)
- Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials (2008) (18)
- Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. (2021) (17)
- EGFR pathway in advanced non-small cell lung cancer. (2011) (17)
- Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer (2019) (17)
- Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. (2021) (17)
- Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. (2020) (17)
- Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer (2011) (16)
- Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. (2015) (16)
- Current state-of-the-art therapy for advanced squamous cell lung cancer. (2013) (16)
- The pulmonary nodule: clinical and radiological characteristics affecting a diagnosis of malignancy (2009) (16)
- Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidence. (2012) (16)
- Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward? (2016) (16)
- Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer. (2020) (15)
- Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. (2015) (15)
- PARP inhibitors: an interesting pathway also for non-small cell lung cancer? (2014) (15)
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors (2013) (15)
- Early Stage Lung Cancer: Progress in the Last 40 Years (2014) (15)
- 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C (2021) (15)
- MET inhibition in lung cancer. (2013) (15)
- Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. (2012) (15)
- Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. (2019) (14)
- Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer. (1999) (14)
- A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). (2016) (14)
- Adjuvant chemotherapy after complete resection for early stage NSCLC. (2003) (14)
- Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
- RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer (2021) (14)
- Chemotherapy for non-small-cell lung cancer. Part 2: Advanced disease. (2003) (14)
- Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. (2014) (14)
- Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (14)
- Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. (2016) (14)
- Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. (2018) (14)
- Exploring the Role of Respiratory Microbiome in Lung Cancer: a Systematic Review. (2021) (13)
- Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non–Small‐cell Lung Cancer: A Systematic Review and Meta‐analysis (2017) (13)
- CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome (2014) (13)
- Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. (2003) (13)
- BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. (2016) (13)
- Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. (2009) (12)
- Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon? (2021) (12)
- Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. (2009) (12)
- Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing (2013) (12)
- Fetal adenocarcinoma of the lung in a 25-year-old woman. (2008) (12)
- Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer (2021) (12)
- RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. (2021) (12)
- Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. (2019) (12)
- A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. (2020) (12)
- Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study (2012) (12)
- European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancer. (2001) (11)
- How Far We Have Come Targeting BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC) (2021) (11)
- Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study (2018) (11)
- Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer (2017) (11)
- PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. (2021) (11)
- Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment (2017) (11)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (2019) (11)
- Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. (2019) (11)
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer. (2015) (11)
- Public health oncology : a framework for progress in low-and middle-income countries † (2012) (10)
- P-523 Phase II trial of BBR3464, a novel, bifunctional platinum analog, as second line treatment of non-small cell lung cancer patients (2003) (10)
- Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. (2020) (10)
- Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871). (2016) (10)
- Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study (2021) (10)
- Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. (2003) (10)
- State of the art in mesothelioma. (2005) (10)
- Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer (2010) (10)
- 1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC (2017) (10)
- Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). (2015) (10)
- Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer (2018) (10)
- Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features (2021) (10)
- Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. (2020) (10)
- Primary pleuropulmonary sarcoma: a rare disease entity. (2012) (10)
- OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses (2019) (9)
- A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. (2022) (9)
- Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread? (2019) (9)
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib (2013) (9)
- Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). (2015) (9)
- 2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
- Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. (2019) (9)
- Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey (2018) (9)
- Double immune checkpoint blockade in advanced NSCLC. (2020) (9)
- Phase I–II and pharmacokinetic study combining gemcitabine (GEM) with oxaliplatin (OX) in patients (pts) with advanced non-small-cell lung (NSCLC) and ovarian carcinoma (OC) (2001) (9)
- Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study (2016) (9)
- Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. (2019) (9)
- P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients (2018) (8)
- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin (2008) (8)
- Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study (2014) (8)
- Lung cancer and women. (2008) (8)
- Toward Therapies Tailored to Patient Characteristics (2007) (8)
- Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972) (2012) (8)
- First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. (2014) (8)
- Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study (2020) (8)
- Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021 (2022) (8)
- Current status of adjuvant chemotherapy in NSCLC. (2006) (8)
- MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts (2018) (8)
- Use of chemo-radiotherapy in locally advanced non-small cell lung cancer. (2002) (8)
- Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis (2021) (8)
- Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) (2019) (8)
- Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. (2014) (8)
- Is there a standard strategy in the management of locally advanced non-small cell lung cancer? (2001) (8)
- Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC (2018) (8)
- Osimertinib-induced Cardiac Dysfunction in EGFR-Mutated Lung Cancer: A Case Series of Five Patients (2018) (7)
- RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis. (2021) (7)
- Low dose CT in early lung cancer diagnosis: Prevalence data. (2005) (7)
- PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine (2013) (7)
- Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine (2020) (7)
- Patients’ Attitudes and Physicians’ Perceptions Toward Maintenance Therapy for Advanced Non–Small‐cell Lung Cancer: A Multicenter Italian Survey (2017) (7)
- NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images (2021) (7)
- NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to in-Vivo Images (2021) (7)
- Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. (2022) (7)
- 375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC (2020) (7)
- An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer (2015) (7)
- Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. (2021) (7)
- Lung Cancer in Italy. (2019) (7)
- Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All? (2021) (7)
- Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of ≥ 1% by the U.S. Food and Drug Administration. (2019) (7)
- Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). (2011) (6)
- Pemetrexed and its emerging role in the treatment of thoracic malignancies (2003) (6)
- PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). (2011) (6)
- Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients (2021) (6)
- Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach (2019) (6)
- MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy (2019) (6)
- P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC (2017) (6)
- ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer. (2001) (6)
- IκBα targeting promotes oxidative stress-dependent cell death (2021) (6)
- Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study (2016) (6)
- Lung Cancer Stage is an Independent Risk Factor for Surgical Mortality (2008) (6)
- Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer (2014) (6)
- Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. (2020) (6)
- Cytotoxic chemotherapy in advanced non-small cell lung cancer. (2005) (6)
- Current development of adjuvant treatment of non-small-cell lung cancer. (2004) (6)
- Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era. (2021) (6)
- Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (2011) (6)
- MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study (2017) (6)
- Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer. (2002) (6)
- MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry (2018) (5)
- MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion (2018) (5)
- MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC (2018) (5)
- Clinical meta-analyses of targeted therapies in adenocarcinoma (2013) (5)
- Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study (2019) (5)
- Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer. (2019) (5)
- Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. (2009) (5)
- Chemotherapy for Non-Small-Cell Lung Cancer, Part II (2003) (5)
- Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial (2017) (5)
- PD3-3-8: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (2007) (5)
- Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) (2020) (5)
- FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC (2021) (5)
- Pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC): Results from a randomized phase III dose finding trial in patients who progressed following platinum-containing chemotherapy: A3-03 (2007) (5)
- Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D). (2014) (5)
- Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma (2018) (5)
- International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. (2021) (5)
- Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer (2017) (5)
- Gemcitabine—Cisplatin chemotherapy followed by radiotherapy in locally advanced non-small cell lung cancer (nsclc): A phase II retrospective analysis (2000) (5)
- Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave (2020) (5)
- An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease (2020) (5)
- The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations (2022) (5)
- Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer. (2001) (5)
- SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit (2020) (5)
- 139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) (2018) (5)
- Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection (2021) (5)
- Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. (2011) (5)
- Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. (2017) (5)
- Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter? (2019) (5)
- Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714). (2012) (4)
- Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC). (2015) (4)
- Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection (2019) (4)
- EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib (2022) (4)
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma (2015) (4)
- Pemetrexed in advanced non-small cell lung cancer: A randomized trial of 500 mg/m2 vs 900 mg/m2 in 588 patients who progressed after platinum-containing chemotherapy (2007) (4)
- Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era (2015) (4)
- Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). (2011) (4)
- PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial (2018) (4)
- OA07.07 Quality of Life (QoL) Analysis in Lung Cancer: A Systematic Review of Phase III Trials Published Between 2012 and 2018 (2019) (4)
- The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. (2022) (4)
- ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC) (2016) (4)
- Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. (2022) (4)
- OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC) (2017) (4)
- C2-02: Factors effecting risk of pneumothorax (PNX) in CT-guided transthoracic needle biopsy of lung lesions: results of 708 consecutive procedures (2007) (4)
- Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. (2015) (4)
- Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? (2019) (4)
- 471PEFFECT OF NINTEDANIB (BIBF 1120) COMBINED WITH STANDARD 2ND-LINE DOCETAXEL IN NSCLC PATIENTS WHO RECEIVED PRIOR PEMETREXED IN LUME-LUNG 1: A RANDOMISED, PLACEBO-CONTROLLED PHASE III TRIAL. (2014) (4)
- Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective. (2021) (3)
- Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. (2022) (3)
- Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy? (2022) (3)
- Repositioning PARP inhibitors in the treatment of thoracic malignancies. (2021) (3)
- Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements (2021) (3)
- Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations (2021) (3)
- Impact of early lung cancer detection on surgical mortality. (2004) (3)
- Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves. (2021) (3)
- Helical-Tip Needle for Transthoracic Percutaneous Image-Guided Biopsy of Lung Tumors: Results of a Pilot Prospective Comparative Study with a Standard Tru-Cut Needle (2017) (3)
- Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma (2021) (3)
- Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis (2018) (3)
- Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results. (2010) (3)
- SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial (2017) (3)
- ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients (2020) (3)
- Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib. (2009) (3)
- Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle? (2018) (3)
- The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer (2021) (3)
- SC10.04 Second-Line Therapy and Beyond in Squamous Cell NSCLC (2017) (3)
- Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC) (2016) (3)
- Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). (2022) (3)
- Improving lung cancer outcomes through smoking cessation: the Women Against Lung Cancer in Europe (WALCE) experience (2020) (3)
- 473PPRIOR TAXANE USE IN THE LUME-LUNG 1 PHASE III TRIAL AND THE EFFECT ON OUTCOME FOLLOWING 2ND-LINE TREATMENT WITH NINTEDANIB (BIBF 1120) AND DOCETAXEL IN PATIENTS WITH ADVANCED NSCLC. (2014) (3)
- P2.04-15 Association Between Opioids and Outcome of 1st Line Immunotherapy in Advanced NSCLC Patients: A Retrospective Evaluation (2019) (3)
- Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. (2019) (3)
- Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial. (2016) (3)
- Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC (2022) (3)
- Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules. (2020) (3)
- O-096 Phase III study in patients with stage IV non small-cell lungcancer (NSCLC) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone (2005) (3)
- Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial. (2013) (3)
- Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821) (2014) (3)
- Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). (2013) (3)
- RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability (2021) (3)
- Gender-Related Differences in Lung Cancer (2018) (3)
- Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study. (2022) (3)
- A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study). (2017) (2)
- Targeted therapy in small cell lung cancer: A new era? (2017) (2)
- 142TiPRANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EVOFOSFAMIDE (TH-302) IN COMBINATION WITH PEMETREXED IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (2015) (2)
- Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature. (2021) (2)
- Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease (2018) (2)
- PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. (2016) (2)
- Next-generation sequencing in malignant pleural mesothelioma: A retrospective study. (2014) (2)
- Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: A case-control study and prevalence data. (2006) (2)
- Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial (2023) (2)
- Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice (2021) (2)
- Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): The use via expanded access to brigatinib (UVEA-Brig) study (2019) (2)
- SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma (2022) (2)
- Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. (2018) (2)
- Gender differences in lung cancer (2016) (2)
- A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM). (2016) (2)
- Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique. (2001) (2)
- Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response. (2022) (2)
- 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC) (2018) (2)
- RNA-based next generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. (2022) (2)
- Erratum: Informal caregiving burden in advance non-small cell lung cancer: The HABIT study (Journal of Thoracic Oncology (2007) 2, 6, (475-480)) (2007) (2)
- MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study. (2018) (2)
- Tumor growth over time in patients with non-small cell lung cancer (NSCLC) of adenocarcinoma histology (ACH) treated with nintedanib and docetaxel or placebo and docetaxel: Analysis of data from the LUME-Lung 1 (LL1) study. (2015) (2)
- Quality of life assessment and reporting in colorectal cancer: a systematic review of phase 3 trials published between 2012 and 2018. (2019) (2)
- NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC). (2012) (2)
- Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small cell lung cancer. (2016) (2)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer (2014) (2)
- P1.14-04 Final Results of the Prospective Genomics of Young Lung Cancer (GYLC), an Addario Lung Cancer Medical Institute Study (2019) (2)
- Postoperative Chemotherapy in Non-Small Cell Lung Cancer (2000) (2)
- 444PD Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK+) NSCLC previously treated with CT and crizotinib (CRZ) (2016) (2)
- PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results (2021) (2)
- Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review (2020) (2)
- P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy (2018) (2)
- Early data of phase III study in patients (pts) with stage IV non-small-cell lung cancer (NSCLC) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone (2004) (1)
- MS13.06 Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma (2019) (1)
- Lung cancer patients and COVID-19 epidemic: an experience from an Italian university hospital (2020) (1)
- Neo-adjuvant chemotherapy prior to surgery in stage III non-small cell lung cancer. (1997) (1)
- 1209P RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome (2021) (1)
- Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer. (2004) (1)
- 85O_PRPatient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer (2017) (1)
- P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial (2019) (1)
- 3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM) (2015) (1)
- P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) (2017) (1)
- P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma: Topic: Mesothelioma and SCLC (2017) (1)
- 6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) (2007) (1)
- S08Cross-cultural adaptation of the US National Cancer Institute's PRO-CTCAE instrument into Italian for adult cancer patients (2016) (1)
- Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis (2022) (1)
- Detection of EGFR mutations in archival lung cancer samples by pyrosequencing (2011) (1)
- [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.] (2021) (1)
- P1.06-005 An International Cohort of Patients with Small Cell Lung Cancer after a Non-Small Cell Lung Carcinoma Oncogene or Non-Oncogene Addicted: Topic: Advanced General (2017) (1)
- P3.08-04 OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC – Trial in Progress (2018) (1)
- LUNG CANCER in women. (2012) (1)
- FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). (2021) (1)
- Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156]. (2019) (1)
- Erythrocyte Mean Corpuscular Volume Change During Pemetrexed Treatment in Advanced Non Small Cell Lung Cancer Patients (2012) (1)
- Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023) (1)
- MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center (2021) (1)
- Infections in lung cancer patients undergoing immunotherapy and targeted therapy: an overview on the current scenario. (2023) (1)
- P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy (2019) (1)
- Intercalated combination of chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis (2016) (1)
- Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease (2020) (1)
- 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC (2011) (1)
- Abstract CT215: RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (PBO+ERL) in previously untreatedEGFRmutation-positive metastatic NSCLC: Next generation sequencing (NGS) results (2020) (1)
- Patients With Lung Cancer and Coronavirus Disease 2019 Epidemic: An Experience From an Italian University Hospital (2020) (1)
- O-143 Gemcitabine-oxaliplatin (GEMOX) chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II study (2003) (1)
- OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers (2021) (1)
- The K751Q polymorphism of XPD gene in lung cancer patients receiving platinum-based chemotherapy. (2004) (1)
- Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer (2021) (1)
- Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. (2022) (1)
- Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC (2019) (1)
- Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (2018) (1)
- Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. (2022) (1)
- Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140) (2016) (1)
- 9153 Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases (2009) (1)
- TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and dou (2016) (1)
- Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. (2022) (1)
- Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report (2019) (1)
- Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU) : Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey (2017) (1)
- Randomized phase 1b/3 study of erlotinib plus ramucirumab in first-line EGFR mut + stage IV NSCLC: phase 1b safety results. (2017) (1)
- PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189 (2019) (1)
- The dream is almost over...don't worry, look ahead. (2003) (1)
- Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise. (2021) (1)
- CD 157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome (2014) (1)
- Secondary biopsy of non‐oncogenic‐driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases (2017) (1)
- PD-010 Pharmacogenetics studies in patients with advanced lung cancer: Prognostic value of the thymidylate synthase 2R/3R polymorphism and predictivity of NER factor XPD K751Q and XRCC1 R399Q polymorphisms following platinum-based chemotherapy (2005) (1)
- Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine. (2015) (1)
- Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer (2014) (1)
- 553 Alternate administration sequences of gemcitabine/vinorelbine in advanced solid tumor: a pharmacokinetic study (2003) (1)
- Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). (2017) (1)
- Lung cancer in Europe: The way forward (2022) (1)
- 793 Multicenter phase II study of gemcitabine-oxaliplatin (GEMOX) chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients (2003) (1)
- A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC). (2012) (1)
- P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC. (2016) (0)
- Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling (2022) (0)
- P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study (2021) (0)
- The way forward: new drugs and new therapeutic strategies in lung cancer therapy. (2006) (0)
- H03*Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study (2015) (0)
- P1.05-050 External Validation of a Prognostic Model for Squamous-Cell Lung Cancer and Impact of Adjuvant Treatment in >1,300 Patients: Topic: Neoadjuvant and Adjuvant Chemotherapy (2017) (0)
- FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC. (2022) (0)
- ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients (2021) (0)
- Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready? (2020) (0)
- 9103 POSTER Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC) (2011) (0)
- P-111 Identification of optimal housekeeping genes for gene expression profiling in non-small cell lung cancer (2005) (0)
- 1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients (2021) (0)
- DNA amount comparison between cytologic and histologic samples for epithelial growth factor receptor (EGFR) testing in non-small-cell lung cancer (NSCLC) patients: a single institution experience. (2017) (0)
- Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy. (2023) (0)
- Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center (2021) (0)
- P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma (2019) (0)
- Underdiagnosis of pulmonary embolism ( PE ) in MDCT for advanced NSCLC : " human factor " as the main cause (2018) (0)
- P2.09-18 Lymphocyte Infiltration Pattern and STING Expression Identify Different Prognostic Groups in Early Stage NSCLC (2019) (0)
- Achievements in targeted therapies (2015) (0)
- P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience (2018) (0)
- Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: A case-control study and prevalence data (2006) (0)
- Afatinib in advanced non-small-cell lung cancer (2013) (0)
- Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now? (2019) (0)
- Drive the oncologists into exercise promotion in lung cancer. (2022) (0)
- P2.03a-017 Chemotherapy-Induced Nausea and Vomiting (CINV) in Italian Lung Cancer Patients: Assessment by Physician, Nurse and Patient: Topic: Clinical Trials (2017) (0)
- Moving through rare lung cancer histologies: a narrative review on diagnosis and treatment of selected infrequent entities (2021) (0)
- Hormone therapy in menopause and lung cancer [Article@Terapie ormonali in menopausa e cancro del polmone] (2009) (0)
- Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer? (2023) (0)
- Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC). (2016) (0)
- P3.06-003 What Do the Children Think about Smoking and How Are They Helped in Prevention? (2017) (0)
- Abstract 4019: RET-MAP: An international multi-center study of patients with advanced non-small cell lung cancer and RET fusions (2022) (0)
- How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer? (2015) (0)
- Phase II study of paclitaxel and carboplatin for advanced Non-Small-Cell Lung-Cancer (2000) (0)
- Pharmacokinetic interactions between gemcitabine (GEM) and vinorelbine (VNR) in patients with advanced stage solid tumors (2001) (0)
- Non small cell lung cancer (NSCLC): accuracy of FGD PET/CT un the preoperative mediastinal nodal staging (2007) (0)
- P1.06-046 Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real-Life Multicenter Study: Topic: Advanced Elderly (2017) (0)
- PUL01.03 Effect of Tumor Size Change and Duration of Response on OS With First-Line Pembrolizumab Plus Pemetrexed-platinum For Metastatic Nonsquamous Non‒Small-Cell Lung Cancer (2021) (0)
- 104P Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features (2021) (0)
- Ef fi cacy of Brigatinib in Patients With Advanced ALK -Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) (2022) (0)
- Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. (2022) (0)
- RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. (2023) (0)
- IκBα targeting promotes oxidative stress-dependent cell death (2021) (0)
- Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC). (2014) (0)
- 1371P Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): results from an EORTC pan-European survey. (2017) (0)
- Immunotherapy and non-small cell lung cancer (2018) (0)
- MS07.04 Future Directions (2018) (0)
- Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome (2010) (0)
- An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples (2023) (0)
- Rociletinib—An Investigational Therapy in Patients with Previously Treated EGFR Mutant-positive Non-small Cell Lung Cancer (2015) (0)
- Abstract 3234: PD-1 is intrinsically expressed by lung cancer cells with stemness features inhibited by PD-1 blockade (2019) (0)
- Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey (2022) (0)
- E09-03: Predictive markers for adjuvant treatment (2007) (0)
- ERCC1 and RRM1 but not EGFR gene expression is predictive of shorter survival in advanced non-small cell lung cancer (NSCLC). (2006) (0)
- P2.04-14 NLR, dNLR and PLR as Possible Predictive Markers in Patients with NSCLC Treated with ICI (2019) (0)
- E09-03 Adjuv ant Treatment for Resectable Lung Cancer, Tue, Sept 4, 16:00 - 17:30 Predictive markers for adjuvant treatment (2007) (0)
- A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) (2019) (0)
- E-68. Are new cytotoxic agents worth investigating? (2003) (0)
- Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients—An Italian Single-Center Experience (2023) (0)
- P2.14-17 Correlation Between Clinic-Pathological Data and T790M Detection in EGFR Mutated NSCLC Patients Progressing on 1st/2nd Generation TKIs (2019) (0)
- Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications. (2023) (0)
- C6-02: Prospective study assessing MDm2 309 and p53 Arg72Pro single nucleotide polymorphism (SNPs) and clinical outcome in advanced lung cancer (2007) (0)
- Integrating psychosocial care into routine cancer care: A stepped-wedge design cluster randomized controlled trial (SWD-RCT) to evaluate effectiveness of the HuCare Quality Improvement Strategy (HQIS) on health-related quality of life (HRQoL). (2019) (0)
- Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer (2022) (0)
- OA04.07 Clinical Characteristics of Lung Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study (2017) (0)
- SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma (2022) (0)
- The need for a comprehensive and integrated approach to lung cancer policy in Europe. (2022) (0)
- Multidisciplinary management of non small cell lung cancer (NSCLC) in stage III: clinical case description. Recommendations and state of the art (2013) (0)
- P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment (2017) (0)
- MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey (2019) (0)
- PO-0779 Current management of limited-stage SCLC and CONVERT trial impact: an EORTC LCG survey (2019) (0)
- GR 01.05 First-Line Management of ALK Mutant NSCLC (2017) (0)
- Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going? (2020) (0)
- Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC): A monocentric study. (2014) (0)
- P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC (2019) (0)
- NON-SMALL-CELL LUNG CANCER (2012) (0)
- Stereotactic ablative radiotherapy (SABR) in non-surgical non small cell lung cancer: Effects on respiratory function (2014) (0)
- Long-term effect of HER-2/neu expression on survival of stage I-IIIA non-small cell lung cancer (NSCLC) patients radically resected (2000) (0)
- H25Immunohistochemistry (IHC) analysis with 3 different antibodies (Abs) and thymidylate synthase (TS) evaluation of FISH-positive ALK-rearranged (ALK+) lung adenocarcinomas (ADK) (2015) (0)
- 9147 POSTER Treatment and Clinical Outcomes of Young Patients (^40 Years) With Advanced Non-small Cell Lung (NSCLC) – Data From a Retrospective Multicentric Database (2011) (0)
- P07Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness: (2015) (0)
- The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions (2021) (0)
- Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing (2013) (0)
- Immunotherapy and non-small cell lung cancers (2017) (0)
- Local for advanced, is this a paradox? (2021) (0)
- Interview: developing therapies for lung cancer. (2017) (0)
- EP1.09-13 Clinic-Pathological and Molecular Features of PD-L1 Analyses in Advanced NSCLC: A Real Life Single Center Experience (2019) (0)
- 1640PPI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC) (2017) (0)
- RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape. (2023) (0)
- Angiogenesis in stage in Non-Small-Cell Lung cancer (NSCLC) expression of Human protesa - activated receptors (PARS) (2004) (0)
- Women and Lung Cancer: Literature Assumptions and News from Recent Publications (2014) (0)
- RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model (2016) (0)
- OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology (2017) (0)
- Early data of phase III study in patients (pts) with stage IV non-small-cell lung cancer (NSCLC) treated with two cycles of cisplatin/gemcitabine followed by a randomization to three additional cycles of the same combination or gemcitabine alone. (2004) (0)
- ERCC1 and TOPOIIa mRNA levels predict response to platinum/etoposide chemotherapy and survival of small-cell lung cancer patients.: PD6-1-2 (2007) (0)
- Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach. (2003) (0)
- Five-year results of a non-randomised study evaluating spiral computed tomography (sCT) for early detection of lung cancer (LC). (2006) (0)
- ALTERED MRNAS EXPRESSION OF GENES INVOLVED IN CELLULAR IRON HOMEOSTASIS IN LUNG NON SMALL CELLS CARCINOMA (2012) (0)
- Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. (2018) (0)
- P-902 Bronchopleural fistula after pneumonectomy for lung cancer:Consideration of 450 consecutive cases (2005) (0)
- R22Immunotherapy (ImT), what Lung Cancer and Melanoma patients (pts) … and physicians, know (2015) (0)
- Immunotherapy & thoracic cancers. (2018) (0)
- 1183PDRISK STRATIFICATION MODEL FOR RESECTED SQUAMOUS CELL LUNG CANCER (R-SQLC) PATIENTS (PTS) ACCORDING TO CLINICAL AND PATHOLOGICAL FACTORS. (2014) (0)
- Malignant Pleural Mesothelioma (2021) (0)
- Pilot study of early repeated 18F-FDG PET during cycle 1 to predict objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC) (2008) (0)
- 15IN SYSTEMIC THERAPY. NON-SMALL CELL LUNG CANCER STAGE I AND II: TREATMENT STANDARDS AND NEW DEVELOPMENT (2009) (0)
- P3.02b-009 Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status: Topic: EGFR Biomarkers (2017) (0)
- EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity (2022) (0)
- P42.01 Tumor Size is an Independent Prognostic Factor after Pulmonary Metastasectomy (2021) (0)
- P2.09-21 Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report (2018) (0)
- Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study (2022) (0)
- P45.12 Renal Function Change During Alectinib in ALK Rearranged Non-Small Cell Lung Cancer: A Retrospective Multicentre Analysis (2021) (0)
- The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey. (2017) (0)
- P-148 ERCC1 and thymidylate synthase expression in malignant pleural mesothelioma (2003) (0)
- PD1-1-5: Five-years results of a non-randomised study evaluating spiral computed tomography (sCT) for early detection of lung cancer (LC) (2007) (0)
- A25The role of health professionals in informing patients with pulmonary diseases to stop smoking: final data of an Italian multicentric survey (2016) (0)
- Results from intermittent and continuous dosing schedules with sunitinib (SU) in previously treated, advanced non–small-cell lung cancer (NSCLC) (2008) (0)
- Impact of early lung cancer detection on surgical mortality (2004) (0)
- Molecular Testing and Treatment Strategies in RET -Rearranged NSCLC Patients: Stay on Target to Look Forward (2022) (0)
- Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer (2016) (0)
- P1-085: Factors affecting diagnostic accuracy of ct-guided transthoracic needle biopsy of lung lesions: results of 660 consecutive procedures (2007) (0)
- EJ. Cancer treatment targeting on HER family (2012) (0)
- Ongoing/planned studies in France Stage I-II NSCLC. (2001) (0)
- Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). (2018) (0)
- The Close Link between Anxiety and Cluster Symptoms in Lung Cancer Patients during First-Line Chemotherapy (2018) (0)
- 1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients (2021) (0)
- Abstract 2163: Gender and estrogens as key factors in the response to immunotherapy in non small cell lung cancer (2022) (0)
- Clinical and biological significance of CD157 in malignant pleural mesothelioma (2011) (0)
- Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells (2022) (0)
- Extrapulmonary findings detected in a low-dose spiral computed tomography (sCT) early detection study for lung cancer (LC). (2006) (0)
- Chapter 17, Achievements in Targeted Therapies - ERS Monographs - Lung Cancer (2015) (0)
- P3.02b-080 Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer: Topic: EGFR Clinical (2017) (0)
- Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC). (2010) (0)
- ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib (2015) (0)
- Differential thymidylate synthase expression in lung cancer adenocarcinoma subtypes. (2014) (0)
- Primary pleuropulmonary sarcoma: what we know about it? (2014) (0)
- Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. (2023) (0)
- Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup (2017) (0)
- PD-025 Prognostic role of Protease-Activated Receptor 1 (PAR-1) and 4(PAR-4) in Stage IB non-small cell lung cancer (NSCLC) (2005) (0)
- Tailored management of advanced squamous non-small cell lung cancer (NSCLC) (2013) (0)
- Cost-control methods of enteral homecare nutrition: the experience of the Pharmaceutical Service (2014) (0)
- 30P Assessing the potential role of RICTOR expression as predictive factor of response to PI3K/mTOR pathway inhibitors in preclinical models of squamous cell lung cancer (2020) (0)
- High DNA polymerase η gene expression is associated with shorter survival in advanced non-small cell lung cancer treated with platinum based chemotherapy (2008) (0)
- MDM2 309 and TP53 Arg72Pro single nucleotide polymorphisms (SNPs) and clinical outcome in advanced lung cancer patients (2007) (0)
- A13Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model (2016) (0)
- Crizotinib: hunting another piece of the lung cancer genome (2012) (0)
- P3.06-008 Employing Remote Web Consenting and Social Media to Facilitate Enrollment to an International Trial on Young Lung Cancer: Topic: Others (2017) (0)
- Human protease-activated receptor-1 and 4 (PAR-1 and PAR-4) expression in stage I non-small cell lung cancer (NSCLC). (2004) (0)
- Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study). (0)
- Clinical impact of ERCC1 and TOPOIIα gene expression in small-cell lung cancer patients treated with platinum/etoposide (2007) (0)
- P2.01-74 Clinical-Pathological Features and Outcome of Patients with Oral Metastases from Lung Cancer: A Multicenter Retrospective Study (2019) (0)
- 1260POUTCOMES OF ELDERLY PATIENTS (≥70 YO) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTI-INSTITUTIONAL ANALYSIS. (2014) (0)
- Predictive molecular pathology in lung cancer: the oncologist point of view (2021) (0)
- SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer. (2019) (0)
- The K751Q polymorphism of XPD gene in lung cancer patients receiving platinum-based chemotherapy (2004) (0)
- 1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (2017) (0)
- 9137 Phase Ib trial (NCT00619424, VEG109607) of pazopanib (GW786034) and erlotinib administered concurrently (2009) (0)
- Inhibition of Tumor Angiogenesis in the Treatment of Lung Cancer (2019) (0)
- 1811P Molecular characterization of epidermal growth factor receptor-mutated (EGFR-m) non-small cell lung cancer (NSCLC) undergoing histological transformation (2021) (0)
- Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2017) (0)
- P1564Atrial fibrillation and thromboembolic prophylaxis: focus on the frail oldest patient. how net clinical benefit influences anticoagulant therapy (2019) (0)
- P1.04-002 Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study (2017) (0)
- 1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) (2021) (0)
- Paclitaxel-based chemotherapy as second-line treatment in small cell lung cancer (SCLC) (2000) (0)
- Sex-Linked Hormone Receptor Expression In Lung Cancer Patients: Pilot Study In A Consecutive Group Of Patients With Advanced Lung Cancer (2011) (0)
- Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Results of 612 consecutive procedures (2016) (0)
- EP08.02-101 Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study (2022) (0)
- Differential expression of DNA repair machinery genes in normal bronchial tissue and non-small cell lung cancer (NSCLC) (2008) (0)
- 463 Vibostolimab plus pembrolizumab with/without docetaxel vs docetaxel in NSCLC after platinum chemotherapy and immunotherapy (2021) (0)
- Afatinib in advanced non-small-cell (2013) (0)
- Winds From the ORIENT: New Data to Inform RATIONAL Choice? (2021) (0)
- H38Prospective molecular profiling of lung cancer patients derived xenografts (2015) (0)
- An international comparison of barriers in opening oncology clinical trials. (2016) (0)
- De fi ning Synchronous Oligometastatic Non – Small Cell Lung Cancer: A Systematic Review (0)
- 1311PNEXT GENERATION SEQUENCING (NGS) REVEALS QUALITATIVE AND QUANTITATIVE MOLECULAR HETEROGENEITY WITHIN EGFR-MUTANT ADVANCED LUNG ADENOCARCINOMA (ALA) PATIENTS (PTS) RECEIVING GEFITINIB (G). (2014) (0)
- P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy (2019) (0)
- A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer (2017) (0)
- The Tradition of the Rising Sun: When Geography Counts. (2018) (0)
- Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial (2019) (0)
- A11Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study (2016) (0)
- 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer (2021) (0)
- Imaging and screening in lung cancer (2008) (0)
- Prognostic nutritional index (pni) in oncogene addicted advanced non-small cell lung cancer (ansclc) patients (pts): an Italian experience (2021) (0)
- P6258Direct oral anticoagulants in non-valvular atrial fibrillation: accuracy of traditional bleeding scores in the elderly (2019) (0)
- Gemcitabine a s S econd-Line T reatment f or A dvanced Non-Small-Cell L ung C ancer: A P hase I I T rial (2012) (0)
- Abstract 6208: Patient-derived organoids from oncogene-addicted lung cancers to define molecular circuits involved in drug resistance (2022) (0)
- 1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC) (2020) (0)
- Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors (2010) (0)
- Pharmacogenetics studies in patients with advanced lungcancer: prognostic value of the thymidylate synthase 2R/3Rpolymorphism and predictivity of NER factor XPD K751Qand XRCC1 R399Q polymorphisms following platinum-basedchemotherapy (2005) (0)
- 94P ESCAT ranking of genomic alterations collected in the Italian Registry of Actionable Mutations (2021) (0)
- EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base (2022) (0)
- Survival data and toxicity profile in advanced non-small cell lung cancer (NSCLC) patients (PTS) treated within or outside controlled clinical trials. (2012) (0)
- Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study (2019) (0)
- P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial (2017) (0)
- Abstract CT020: Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma (2018) (0)
- Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. (2019) (0)
- Retrospective Study of Radiological Findings of Pulmonary Embolisms (PE) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
- 140P Prognostic and predictive value of co-mutational profile in advanced EGFR positive NSCLC patients treated with TKIs (2021) (0)
- P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma (2018) (0)
- 30 Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: results of the phase III, randomised, double-blind LUME-Lung 1 trial (2014) (0)
- P14.03 Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy (2021) (0)
- Clonal Heterogeneity in Non-Small Cell Lung Cancer and the Possible Role in Predicting Response to Treatment with Immune Checkpoint Inhibitors (2018) (0)
- H09The role of health care professionals in smoking cessation among patients with pulmonary diseases: an Italian multicentric survey (2015) (0)
- P-190 A prognostic factors analysis of fractionated stereotactic radiotherapy in the treatment of patients with brain metastases from non small cell lung carcinoma (2003) (0)
- FP08.04 Tumour Spread Through Air Space (STAS) In Lung Metastases (2021) (0)
- P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis (2019) (0)
- 3102 Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: Analysis of data from the LUME-Lung 1 study (2015) (0)
- Preliminary data from a prospective case registry of European women with lung cancer: a WALCE (Women Against Lung Cancer in Europe) Project: P1-043 (2007) (0)
- Prevalence of non-calcified nodular lesions in a high risk population evaluated by low dose helical computed tomography (hCT) of the chest. Results of a feasibility study (2003) (0)
- P2.03b-063 Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study: Topic: Biomarkers (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Silvia Novello?
Silvia Novello is affiliated with the following schools:
